Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Alternative splicing of NF-YA promotes prostate cancer aggressiveness and represents a new molecular marker for clinical stratification of patients

Fig. 1

Expression of NF-YA and its splice variants in prostate cancer samples. A Expression levels of NF-YA, NF-YB and NF-YC measured as transcripts per million (TPM) in prostate adenocarcinoma (PRAD) patients compared to normal ones. N = normal samples, T = tumor samples. Wilcoxon test T vs N: **p < 0.01, ****p < 0.0001. B Transcript levels (TPM) of NF-Y subunits in PRAD patients according to Gleason Score stratification. Wilcoxon test T vs N: **p < 0.01, ***p < 0.001, ****p < 0.0001, ns, not significant. Jonckheere trend test: §§§§ p < 0.0001. C NF-YA expression levels in PRAD samples stratified by pathological T stage. Jonckheere trend test: §§§§ p < 0.0001. D NF-YA expression levels in PRAD samples stratified by pathological N stage. Wilcoxon test N1 vs N0: **p < 0.01. E Transcript levels (TPM) of NF-YAs and NF-YAl in PRAD patients compared to normal ones from TCGA data set. N = normal samples, T = tumor samples. Wilcoxon test T vs N: ****p < 0.0001. F TPM of NF-YAs and NF-YAl in PRAD patients according to Gleason Score stratification. Wilcoxon test: **p < 0.01, ***p < 0.001, ****p < 0.0001, ns, not significant. Jonckheere trend test: §§§§ p < 0.0001. G Transcript levels (TPM) of NF-YA isoforms according to pathological T stage. Jonckheere trend test: §§§§ p < 0.0001. H Transcript levels (TPM) of NF-YA isoforms according to pathological N stage. Wilcoxon test N1 vs N0: *p < 0.05, **p < 0.01

Back to article page